» Articles » PMID: 10073286

The Prognostic Significance of Altered Cyclin-dependent Kinase Inhibitors in Human Cancer

Overview
Journal Annu Rev Med
Publisher Annual Reviews
Specialty General Medicine
Date 1999 Mar 12
PMID 10073286
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Progression through the cell cycle is governed by cyclin-dependent kinases (cdks), whose activity is inhibited by the cdk inhibitors. Cyclins, cdks, and cdk inhibitors are frequently deregulated in cancers. This chapter reviews the prognostic significance of alterations in cdk inhibitors. Loss of p27 protein provides independent prognostic information in breast, prostate, colon, and gastric carcinomas, and immunohistochemical (IHC) staining for p27 may eventually become part of routine histopathologic processing of cancers. Loss of IHC staining for p21 may be prognostic in certain cancers but conflicting results are reported in breast cancer. Reports on homozygous deletion of p16 and p15 genes suggest the value of larger, prospective studies with standardized treatment protocols to definitively establish the prognostic utility of p15/p16 deletions in acute leukemias. Larger trials and the development of a consensus on methods for deletion analysis, IHC staining, and tumor scoring will be needed to move these molecular assays from bench to bedside.

Citing Articles

Odontogenic Carcinosarcoma: Clinicopathologic and Molecular Features of Three Cases, a Literature Review and Nomenclature Proposal.

Cole G, Chi A, Cook D, Kubik M, Bilodeau E, Seethala R Head Neck Pathol. 2023; 17(3):751-767.

PMID: 37486533 PMC: 10513988. DOI: 10.1007/s12105-023-01569-3.


Candidate targets of copy number deletion events across 17 cancer types.

Huang Q, Baudis M Front Genet. 2023; 13:1017657.

PMID: 36726722 PMC: 9885371. DOI: 10.3389/fgene.2022.1017657.


Understanding Retinoblastoma Post-Translational Regulation for the Design of Targeted Cancer Therapies.

Janostiak R, Torres-Sanchez A, Posas F, de Nadal E Cancers (Basel). 2022; 14(5).

PMID: 35267571 PMC: 8909233. DOI: 10.3390/cancers14051265.


Monepantel antitumor activity is mediated through inhibition of major cell cycle and tumor growth signaling pathways.

Bahrami F, Mekkawy A, Badar S, Morris D, Pourgholami M Am J Cancer Res. 2021; 11(6):3098-3110.

PMID: 34249447 PMC: 8263694.


The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Tundo G, Sbardella D, Santoro A, Coletta A, Oddone F, Grasso G Pharmacol Ther. 2020; 213:107579.

PMID: 32442437 PMC: 7236745. DOI: 10.1016/j.pharmthera.2020.107579.